SAVARA INC (SVRA)
Health Care · Clinical-stage biopharmaceutical company focused on rare/orphan respiratory diseases · NASDAQ
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
What SAVARA INC does
Savara Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of medicines to treat rare and orphan respiratory diseases. The company is advancing product candidates through clinical trials with the aim of addressing unmet medical needs in respiratory conditions. Savara operates as an early-stage pharmaceutical development company with research and development as its primary operational focus, supported by general and administrative functions to manage regulatory, clinical, and corporate activities.
Themes: Rare respiratory diseases, Orphan drugs, Clinical development, Biopharmaceutical development, Clinical trial failure or inconclusive data results for product candidates could delay or prevent regulatory approvals, Substantial operating expenses and negative cash flows with limited cash runway; company is unprofitable and dependent on continued funding, Regulatory approval uncertainty; inability to obtain or maintain necessary regulatory approvals could prevent commercialization of product candidates, Genentech (rare respiratory disease developers), Boehringer Ingelheim (pulmonary fibrosis focus), Roche (orphan and rare disease portfolio)
Fundamentals
- Price$5.59 as of 2026-08-21 close
- Market cap$1.1B as of 2026-08-21
- 1-year return+83.3% 2025-08-21 close $3.05 → 2026-08-21 close $5.59
- P/En/a negative earnings
- Net margin-4253.9% as of 2026-08-24
- Gross margin+100.0% as of 2026-08-24
- ROE-87.2% as of 2026-08-24
- Debt / equity0.17 as of 2026-08-24
- Beta0.19 as of 2026-08-24
- Last reported earnings2020-08-06 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How SVRA compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SAVARA INC looks technically
SAVARA INC (SVRA) is trading 1.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 232 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 7 trading days ago. It is 20.2% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 1.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.67 | $5.67 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.49 | $5.49 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 5.14. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 232 trading days ago — a "golden cross", a bullish long-term signal | 232 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 1.8% above | +1.8% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 13.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 51.1 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($5.14 to $5.99) — its "stochastic" reading is 53 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 52.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.00 | $7.00 |
|---|---|---|
| From the 52-week high | it is 20.2% below its 52-week high (its highest price of the past year) | -20.2% |
| Above the 52-week low | it is 108.6% above its 52-week low (its lowest price of the past year) | +108.6% |
| Below the 52-week high | it is 20.2% below its highest point of the past year | 20.2% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $9553.57 (set on 2006-04-20) | $9553.57 |
| Given back of the 52-week move | over the past year its closes ranged ($3.01 to $6.94), and it has given back roughly a third of its rise from last year’s low — 34% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.39 to $4.51. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.4% |
| From the all-time high | it is 99.9% below its all-time high | -99.9% |
| Nearest price level | it is trading 2.9% above a support level at $5.43 — a price it turned at four times since 2026-01-05, most recently on 2026-07-17. Since 2024-08-21 it has 12 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.9% |
| All-time low | its lowest closing price on record is $0.69 (set on 2019-11-14) | $0.69 |
| Above the all-time low | it is 710.1% above its all-time low | +710.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2711 between its high and its low — about 4.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2711 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.17 and $5.82 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.17 – $5.50 – $5.82 |
| Typical daily range (% of price) | its price moves about 4.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.8% |
| Stretch from the 200-day average | it is trading 0.4 daily ranges above its 200-day average price (1.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.84× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.9% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.6 percentage points (the stock lost 4.3% while the market gained 2.3%) | -6.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 7.4 percentage points (the stock gained 10.5% while the market gained 3.1%) | +7.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 10.0 percentage points (the stock gained 1.1% while the market gained 11.1%) | -10.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 62.8 percentage points (the stock gained 83.3% while the market gained 20.5%) | +62.8% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 4.8% of the share price. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.52 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +1.3% |
|---|
Price levels it has turned at before
SVRA last closed at $5.59 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.43 | Support | 2.9% below the last close | turned there four times · 2026-01-05 to 2026-07-17 |
| $6.03 | Resistance | 7.8% above the last close | turned there three times · 2026-02-13 to 2026-08-07 |
| $5.14 | Support | 8.1% below the last close | turned there three times · 2026-02-11 to 2026-08-14 |
| $4.82 | Support | 13.7% below the last close | turned there twice · 2026-03-24 to 2026-04-29 |
| $6.48 | Resistance | 16.0% above the last close | turned there twice · 2026-01-22 to 2026-07-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $5.14.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$10.94 range $9.00 – $16.00; median $10.25
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SVRA
- Consensus EPS estimate-$0.146 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant risk of failure in clinical trials and the inability to obtain regulatory approval for its sole product candidate.","Extensive legal and compliance risks related to healthcare regulations, including the False Claims Act and Anti-Kickback Statute.","High volatility of common stock, which is typical for early-stage biotechnology companies."]
What changed in the latest 10-Q
AI-assisted comparison of SVRA's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
The two filings could not be meaningfully compared for this section.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($2M) — 1 selling insider
- Last 180 days0 buys · 1 sell ($2M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-22. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SVRA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SVRA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 19,533,507
- Reported value $106,652,947
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SVRA had 36,819,551 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SVRA had 17.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 20.13 days to cover at the same settlement.
- Reported short interest (shares) 36,819,551
- Short interest (% of shares outstanding) 17.9%
- Prior settlement (shares) 34,140,223
- Reported change 7.85%
- Days to cover (reported) 20.13
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
SAVARA INC is found in…
SVRA ranks in…
Frequently asked questions
What does SAVARA INC (SVRA) do?
Savara Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of medicines to treat rare and orphan respiratory diseases. The company is advancing product candidates through clinical trials with the aim of addressing unmet medical needs in respiratory conditions.
What sector is SAVARA INC (SVRA) in?
SAVARA INC (SVRA) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceutical company focused on rare/orphan respiratory diseases. It trades on NASDAQ.
Is SAVARA INC (SVRA) overbought or oversold right now?
SAVARA INC (SVRA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SVRA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.